Evaluation of PCR Negativity in Respiratory Specimens of COVID-19 Patients After Hydroxychloroquine and/or Favipiravir Treatment

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Klimik Journal Pub Date : 2022-12-26 DOI:10.36519/kd.2022.4268

Gunay Tuncer-Ertem, Ayse Buyukdemirci, Filiz Demirel, M. Ozsoy, Fatma Sebnem Erdinc, C. Ataman-Hatipoglu, Ulku Oztoprak-Siyah, S. Cesur, S. Kınıklı, Pinar Gurkaynak, Erkan Buyukdemirci

{"title":"Evaluation of PCR Negativity in Respiratory Specimens of COVID-19 Patients After Hydroxychloroquine and/or Favipiravir Treatment","authors":"Gunay Tuncer-Ertem, Ayse Buyukdemirci, Filiz Demirel, M. Ozsoy, Fatma Sebnem Erdinc, C. Ataman-Hatipoglu, Ulku Oztoprak-Siyah, S. Cesur, S. Kınıklı, Pinar Gurkaynak, Erkan Buyukdemirci","doi":"10.36519/kd.2022.4268","DOIUrl":null,"url":null,"abstract":"Objective: We evaluated PCR negativity in oropharyngeal and nasopharyngeal secretions of COVID-19 patients at the end of hydroxychloroquine and/or favipiravir treatments. \n\nMethods: Study inclusion criteria were being hospitalized, being older than 18 years, PCR positivity in oropharyngeal and nasopharyngeal secretions and being tested for SARS CoV-2-RNA PCR after treatment. Initially hydroxychloroquine treatment (group 1) was administered to the patients according to COVID-19 guide of Health Ministry. Favipiravir (group 2) alone or in combination with hydroxychloroquine (group 3) was administered to patients who were unresponsive to hydroxychloroquine or had severe pneumonia or were admitted to intensive care unit. Control respiratory specimens were taken no earlier than 24 hours, after the end of therapy. Repeated tests with 24–48-hour intervals were performed in patients with still positive PCR test results. The detection of SARS CoV-2-RNA was made by real-time PCR.\nResults: The study group included 492 patients who received treatment. Mean duration of symptoms was similar among three groups. PCR negativity rate was 52.8% in the specimens taken 24 hours after the end of treatment. PCR negativity rates was 27.9% (200/492) in 48 hours after the end of treatment, %13.8 (123/492) in 72nd hour and %3.8 (80/492) in 96th hour. The ratios of PCR negativity for all specimen days were similar in three groups. There was no statistically significant difference between the groups for time to PCR negativity from the date of positivity and after the end of treatment. We determined that early or late treatment did not make a difference in terms PCR negativity time.\nConclusion: No difference was found in terms of the ratios of PCR negativity or time for negativity in oropharyngeal and/or nasopharyngeal specimens taken after the end of treatment in COVID-19 patients receiving hydroxychloroquine and/or favipiravir treatment.","PeriodicalId":44309,"journal":{"name":"Klimik Journal","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2022-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klimik Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36519/kd.2022.4268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We evaluated PCR negativity in oropharyngeal and nasopharyngeal secretions of COVID-19 patients at the end of hydroxychloroquine and/or favipiravir treatments. Methods: Study inclusion criteria were being hospitalized, being older than 18 years, PCR positivity in oropharyngeal and nasopharyngeal secretions and being tested for SARS CoV-2-RNA PCR after treatment. Initially hydroxychloroquine treatment (group 1) was administered to the patients according to COVID-19 guide of Health Ministry. Favipiravir (group 2) alone or in combination with hydroxychloroquine (group 3) was administered to patients who were unresponsive to hydroxychloroquine or had severe pneumonia or were admitted to intensive care unit. Control respiratory specimens were taken no earlier than 24 hours, after the end of therapy. Repeated tests with 24–48-hour intervals were performed in patients with still positive PCR test results. The detection of SARS CoV-2-RNA was made by real-time PCR. Results: The study group included 492 patients who received treatment. Mean duration of symptoms was similar among three groups. PCR negativity rate was 52.8% in the specimens taken 24 hours after the end of treatment. PCR negativity rates was 27.9% (200/492) in 48 hours after the end of treatment, %13.8 (123/492) in 72nd hour and %3.8 (80/492) in 96th hour. The ratios of PCR negativity for all specimen days were similar in three groups. There was no statistically significant difference between the groups for time to PCR negativity from the date of positivity and after the end of treatment. We determined that early or late treatment did not make a difference in terms PCR negativity time. Conclusion: No difference was found in terms of the ratios of PCR negativity or time for negativity in oropharyngeal and/or nasopharyngeal specimens taken after the end of treatment in COVID-19 patients receiving hydroxychloroquine and/or favipiravir treatment.

查看原文本刊更多论文

新冠肺炎患者接受羟氯喹和/或法维匹拉韦治疗后呼吸道标本中PCR阴性的评估

目的：我们评估新冠肺炎患者在羟氯喹和/或法匹拉韦治疗结束时口咽和鼻咽分泌物中的PCR阴性。方法：研究纳入标准为住院患者、年龄超过18岁、口咽和鼻咽分泌物中的PCR阳性以及治疗后的SARS-CoV-2-RNA PCR检测。最初，根据卫生部新冠肺炎指南，对患者进行羟氯喹治疗（第1组）。法维匹拉韦（第2组）单独或与羟氯喹联合用药（第3组）用于对羟氯喹无反应或患有严重肺炎或入住重症监护室的患者。对照呼吸标本在治疗结束后24小时内采集。对PCR检测结果仍然呈阳性的患者进行了间隔24-48小时的重复检测。结果：研究组包括492例接受治疗的患者。三组患者的平均症状持续时间相似。在治疗结束后24小时采集的标本中，PCR阴性率为52.8%。治疗结束后48小时PCR阴性率为27.9%（200/492），72小时为%13.8%（123/492）和96小时为%3.8%（80/492）。三组所有标本日的PCR阴性率相似。从阳性日期到治疗结束，两组之间的PCR阴性时间没有统计学上的显著差异。我们确定早期或晚期治疗对PCR阴性时间没有影响。结论：在接受羟氯喹和/或法匹拉韦治疗的新冠肺炎患者治疗结束后采集的口咽和/或鼻咽标本中，PCR阴性率或阴性时间没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Klimik Journal MEDICINE, GENERAL & INTERNAL-

CiteScore

0.60

自引率

33.30%

发文量